Method of producing a composite material

文档序号:1471582 发布日期:2020-02-21 浏览:32次 中文

阅读说明:本技术 方法 (Method of producing a composite material ) 是由 H·G·内登 V·朱尔西克 G·塔拉维拉 于 2018-07-04 设计创作,主要内容包括:本发明提供式(I)的茂金属基化合物。R<Sup>a</Sup>、R<Sup>b</Sup>、R<Sup>c</Sup>、R<Sup>d</Sup>、R<Sup>e</Sup>、R<Sup>f</Sup>、M、m、n、j、k、Y和Z和*如说明书所述。本发明还提供一种制备该络合物的方法,一种增加式(II)的化合物光学纯度的方法,和一种将式(V)的茂金属基化合物非对称转移氢化(ATH)成式(IV)的茂金属基化合物的方法。<Image he="806" wi="700" file="DDA0002357433180000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(The present invention provides metallocene-based compounds of formula (I). R a 、R b 、R c 、R d 、R e 、R f M, M, n, j, k, Y and Z and are as described in the specification. The invention also provides a process for preparing the complex, a process for increasing the optical purity of the compound of formula (II), and a process for the Asymmetric Transfer Hydrogenation (ATH) of a metallocene-based compound of formula (V) to a metallocene-based compound of formula (IV).)

1. A metallocene-based compound of the formula (I),

Figure FDA0002357433160000011

wherein:

Ra、Rb、Rcand RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

2. The metallocene-based compound of claim 1, wherein RaIs methyl.

3. The metallocene-based compound according to claim 1 or 2, wherein j is 0.

4. The metallocene-based compound of any one of the preceding claims, wherein m is 0.

5. The metallocene-based compound of any one of the preceding claims, wherein n is 0.

6. The metallocene-based compound of any one of the preceding claims, wherein RaIs methyl, and m, n and j are 0.

7. The metallocene-based compound of claim 1 or 2, wherein j is 1.

8. The metallocene-based compound of claim 1, 2, or 7, wherein RdIs methyl.

9. The metallocene-based compound of any one of the preceding claims, wherein ReAnd RfIs methyl.

10. The metallocene-based compound according to any one of the preceding claims, wherein M is Fe, Ru and Os, preferably Fe.

11. The metallocene-based compound of any one of the preceding claims, wherein Z is selected from the group consisting of a monoatomic anion, an oxoanion, and an organic anion.

12. The metallocene-based compound according to claim 11, wherein the oxoanion is (H)2PO4)-Or (HPO)4)2-

13. The metallocene-based compound of claim 11, wherein Z is a monoanion or a dianion.

14. A process for the preparation of a metallocene-based compound of formula (I),

Figure FDA0002357433160000031

comprising reacting a compound of formula (II) with H.acidor in a solventk(j+1)Z are mixed to form the compound of formula (I),

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

15. A method according to claim 14, wherein hk(j+1)Z is H3PO4Fumaric acid, adipic acid, oxalic acid, benzoic acid, acetic acid, methanesulfonic acid and p-toluenesulfonic acid.

16. The method according to claims 14 and 15, wherein the solvent is selected from alcohols, ethers, aromatic solvents, esters or combinations thereof.

17. The method according to claim 16, wherein the solvent is an alcohol.

18. The method of claim 17, wherein the alcohol is methanol.

19. The method of claims 14-18, further comprising obtaining the metallocene-based compound of formula (II) from the metallocene-based compound of formula (I) in the presence of a base.

20. A process for increasing the optical purity of a compound of formula (II),

Figure FDA0002357433160000041

which comprises the following steps:

a) mixing a metallocene-based compound of formula (I) with a solvent to obtain a suspension of solid particles in a liquid, wherein the mixing is carried out around the boiling point of the solvent;

b) separating the metallocene-based compound of formula (I) in solid form from the suspension of step a);

c) obtaining a compound of formula (II) from the metallocene-based compound of formula (I) of step b) in the presence of a base,

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl radicals, not takingSubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

21. The method of claims 14-19, further comprising a method of increasing the optical purity of the compound of formula (II),

Figure FDA0002357433160000051

which comprises the following steps:

a) mixing a metallocene-based compound of formula (I) with a solvent to obtain a suspension of solid particles in a liquid, wherein the mixing is carried out around the boiling point of the solvent;

b) separating the metallocene-based compound of formula (I) in solid form from the suspension of step a);

c) obtaining the compound of formula (II) from the metallocene-based compound of formula (I) of step b) in the presence of a base.

22. The method according to claim 20 or 21, wherein the compound of formula (I) is compound a (H)2PO4) And the compound of formula (II) is compound B:

Figure FDA0002357433160000061

23. the method of claims 20-22, wherein the solvent comprises an alcohol.

24. The method according to claim 23, wherein the alcohol is selected from methanol, n-propanol, isopropanol or a combination thereof.

25. The method of claims 20-24, wherein the base is sodium hydroxide.

26. The process of claims 22-25, wherein the enantiomeric excess of compound B is ≥ 99% ee.

27. The method of claims 14-19 and 21-26, wherein the compound of formula (III) is prepared by reacting a compound of formula (III) with a compound of formula HNR in a solventeRfTo form a compound of formula (II), thereby preparing a compound of formula (II),

Figure FDA0002357433160000062

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5;

when j is 1, n is an integer of 0 to 4; and

denotes an optically active carbon atom.

28. The method of claim 27, wherein the solvent comprises an alcohol and C1-C8A mixture of alkanes.

29. The process according to claim 28, wherein the alcohol is a mixture of isopropanol and heptane or a mixture of isopropanol and cyclohexane.

30. The process of claims 27-29, wherein the compound of formula (III) is prepared by forming a compound of formula (III) by mixing a compound of formula (IV) with a compound of formula acyl-LG in the presence of a base, wherein LG is a leaving group:

Figure FDA0002357433160000071

31. the method of claim 30, wherein the compound of formula acyl-LG is a carboxylic acid anhydride or an acid chloride.

32. The method according to claims 30 and 31, wherein the compound of formula acyl-LG is acetic anhydride.

33. The method of claims 30-32, wherein the base is sodium acetate.

34. The method of claim 33, wherein the sodium acetate is NaOAc-3H2O。

35. The method of claims 30-34, further comprising a solvent.

36. The method according to claim 35, wherein the solvent is an aprotic solvent.

37. The method according to claim 36, wherein the aprotic solvent is heptane.

38. The method of claims 30-32, 36 and 37, wherein the base is Dimethylaminopyridine (DMAP).

39. The process of any one of claims 30-38, wherein the compound of formula (IV) is prepared by Asymmetric Transfer Hydrogenation (ATH) of a metallocene-based compound of formula (V),

Figure FDA0002357433160000081

wherein:

the asymmetric transfer hydrogenation is carried out in an aqueous solvent in the presence of an asymmetric transfer hydrogenation catalyst and active formic acid at a temperature of greater than 60 ℃;

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, toSubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5;

when j is 1, n is an integer of 0 to 4; and

denotes an optically active carbon atom.

40. The method according to any one of claims 14-19 and 21-39, wherein the compound of formula (I) is compound A (H)2PO4) The compound of formula (II) is compound B, the compound of formula (III) is compound C, the compound of formula (IV) is compound D:

41. the method of claim 38, further comprising the step of:

a) adding methanol to a solution containing DMAP & H3Compound A (H) of PO and DMAP HOAc2PO4) To produce a solid-liquid mixture;

b) will contain compound A (H)2PO4) And DMAP HOAc from the solid-liquid mixture of step a);

c) adding DMAP HOAc-containing compound A (H)2PO4) Separating from the liquid of step b);

d) adding dichloromethane or acetonitrile to the separated compound A (H) containing DMAP HOAc of step c)2PO4) To produce a second solid-liquid mixture;

e) separating the solid from the second solid-liquid mixture of step d) to produce a purity ratioHigh Compound A (H) before Steps a) -e)2PO4)。

42. The method of claims 27-41, wherein the peptide is conjugated to a peptide of formula HNReRfThe compound of formula (III) is obtained in situ prior to the reaction.

43. A process for the Asymmetric Transfer Hydrogenation (ATH) of a metallocene-based compound of the formula (V) to a metallocene-based compound of the formula (IV),

Figure FDA0002357433160000101

wherein:

the asymmetric transfer hydrogenation is carried out in an aqueous solvent in the presence of an asymmetric transfer hydrogenation catalyst and active formic acid at a temperature of greater than 60 ℃;

wherein:

Ra、Rb、Rcand RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5;

when j is 1, n is an integer of 0 to 4; and

denotes an optically active carbon atom.

44. The method of claim 43, wherein RaIs methyl.

45. The method of claim 43 or 44, wherein j is 0.

46. The method of any one of claims 43-45, wherein m is 0.

47. The method of any one of claims 43-46, wherein n is 0.

48. The method of any one of claims 43-47, wherein RaIs methyl and m, n and j are 0.

49. The method of claim 43 or 44, wherein j is 1.

50. The method of claim 43, 44, or 49, wherein RdIs methyl.

51. The method of any one of claims 43-50, wherein ReAnd RfIs methyl.

52. The method according to any one of claims 43-51, wherein the asymmetric transfer hydrogenation catalyst is a complex of formula (VI):

Figure FDA0002357433160000111

wherein the content of the first and second substances,

R1、R2、R3、R4and R5Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, CN, -NR20R21、-COOH、COOR20、-CONH2、-CONR20R21and-CF3Wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR30R31、-COOR30、-CONR30R31and-CF3(ii) a And/or

R1And R2、R2And R3、R3And R4Or R4And R5Together form an aromatic ring containing 6 to 10 carbon atoms, optionally substituted with: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3

R6、R7、R8And R9Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl and optionally substituted C6-20Aryloxy, wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3Or is or

R6And R7Together with the carbon atom to which they are bonded and/or R8And R9Together with the carbon atom to which they are bonded form optionally substituted C3-20Cycloalkyl or optionally substituted C2-20Cycloalkoxy, wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3Or is or

R6And R7One of and R8And R9Together form an optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are independently selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3

Provided that R is6And R7And/or R8And R9In contrast to this, the present invention is,

Figure FDA0002357433160000121

R10is optionally substituted straight, branched or cyclic C1-10Alkyl, optionally substituted C6-10Aryl or-NR11R12Wherein the substituents are selected from: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radicals,C6-10Aryloxy, -Hal, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3

R11And R12Independently selected from hydrogen, optionally substituted straight, branched or cyclic C1-10Alkyl and optionally substituted C6-10Aryl, wherein the substituents are selected from the following: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3Or is or

R11And R12Together with the nitrogen atom to which they are bonded form optionally substituted C2-10Cycloalkyl-amino, wherein the substituents are selected from: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3

R20And R21Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN, -NR30R31、-COOR30、-CONR30R31and-CF3Wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

R30And R31Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branchedOr cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN and-CF3Wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

A is optionally substituted straight or branched chain C2-5Alkyl, wherein the substituents are selected from: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl and C6-10Aryloxy group, or

A is a group of formula (VII):

Figure FDA0002357433160000131

wherein p is an integer selected from 1, 2, 3 or 4;

each R40Independently selected from linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN or-CF3

q and r are independently selected from integers of 0, 1, 2 or 3, wherein q + r is 1, 2 or 3;

each R41Independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3(ii) a Or

A is a group of formula (VIII):

x is O or S;

s and t are independently integers selected from 0, 1, 2 or 3, wherein s + t is 1, 2 or 3;

each R42Independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

And

hal is halogen.

53. The method according to any one of claims 43-52, wherein the asymmetric transfer hydrogenation catalyst is a complex of formula (IX):

Figure FDA0002357433160000142

wherein the content of the first and second substances,

R101、R102、R103、R104、R105and R106Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, CN, -NR200R201、-COOH、COOR200、-CONH2、-CONR200R201and-CF3Wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR300R301、-COOR300、-CONR300R301and-CF3(ii) a And/or

R101And R102、R102And R103、R103And R104、R104And R105Or R105And R106Together form an aromatic ring containing 6 to 10 carbon atoms, optionally substituted with: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3

R107、R108、R109And R110Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl and optionally substituted C6-20Aryloxy, wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3Or is or

R107And R108Together with the carbon atom to which they are bonded and/or R109And R110Together with the carbon atom to which they are bonded form optionally substituted C3-20Cycloalkyl or optionally substituted C2-20Cycloalkoxy, wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3Or is or

R107And R108One of and R109And R110Together form an optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are independently selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3

Provided that R is107And R108And/or R109And R110In contrast to this, the present invention is,

Figure FDA0002357433160000161

R111is optionally substituted straight, branched or cyclic C1-10Alkyl, optionally substituted C6-10Aryl or-NR112R113Wherein the substituents are selected from: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -Hal, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3

R112And R113Independently selected from hydrogen, optionally substituted straight, branched or cyclic C1-10Alkyl and optionally substituted C6-10Aryl, wherein the substituents are selected from: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3Or is or

R112And R113Together with the nitrogen atom to which they are bonded form optionally substituted C2-10Cycloalkyl-amino, wherein the substituents are selected from: one or more straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3

R200And R201Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN, -NR30R31、-COOR300、-CONR300R301and-CF3Wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

R300And R301Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN and-CF3Wherein the substituents are selected from: one or more straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

And

hal' is halogen.

54. The method according to any one of claims 43-53, wherein the aqueous solvent is water or a mixture of water and a water-miscible solvent.

55. The process of any one of claims 43-54, wherein the asymmetric transfer hydrogenation reaction is carried out at one or more temperatures in the range of ≥ about 60 ℃ to ≤ about 100 ℃.

56. The method according to any one of claims 43-55, wherein the active formic acid is a mixture of formic acid, a tertiary amine base, and optionally water.

57. A process according to claim 56, wherein the tertiary amine base is triethylamine.

58. The method as set forth in claim 57 wherein the molar ratio of formic acid to tertiary amine is in the range of from about 1:1 to about 1.2:1 mol.

59. The method according to any one of claims 57 or 58, wherein the active formic acid is a mixture of formic acid, tertiary amine, and water, and the concentration of formic acid to tertiary amine is in the range of 1M:1M to about 1.2M: 1M.

60. The process of any one of claims 43-59, wherein the molar ratio of the metallocene-based compound of formula (V) to the asymmetric transfer hydrogenation catalyst is in the range of about 100:1 to about 2000: 1.

61. The method of claim 60, wherein the molar ratio is ≧ about 600: 1.

62. The method of any one of claims 43-61, wherein M is Fe, and M is 0, 1, 2, or 3, and with-RaC*At least one of the carbon atoms ortho to the H (OH) group is unsubstituted and further comprises converting the metallocene-based alcohol of formula (IV) into a Bophoz or Josiphos ligand.

63. The method of claims 14-19 and 27-62, wherein the enantiomeric excess of the compound of formula (II) is ≥ 97%.

Disclosure of Invention

The present invention provides quaternary ammonium salts of metallocene-containing amines in high purity and/or high enantiomeric excess, which are obtained in high yields. In certain embodiments, the quaternary ammonium salts of the metallocene-containing amines have high chemical purity. In certain embodiments, the quaternary ammonium salts of the metallocene-containing amines have a high enantiomeric excess.

The present invention is also more suitable for large scale production of optically active metallocene-based alcohols. In certain embodiments, the ATH process produces optically active metallocene-based alcohols in high yields. In certain embodiments, the ATH process produces optically active metallocene-based alcohols in high enantiomeric excess.

The present invention accordingly provides a metallocene-based compound of the formula (I),

Figure BDA0002357433170000021

wherein:

Ra、Rb、Rcand RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

In another aspect, the present invention provides a process for the preparation of a metallocene-based compound of formula (I),

Figure BDA0002357433170000031

comprising reacting a compound of formula (II) with H H.tartatek(j+1)Z in a solvent to form a compound of formula (I),

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

In yet another aspect, there is provided a method of increasing the optical purity of a compound of formula (II),

Figure BDA0002357433170000041

which comprises the following steps:

a) mixing a metallocene-based compound of formula (I) with a solvent to obtain a suspension of solid particles in a liquid, wherein the mixing is carried out around the boiling point of the solvent;

b) separating the metallocene-based compound of formula (I) in solid form from the suspension of step a);

c) obtaining a compound of formula (II) from the metallocene-based compound of formula (I) of step b) in the presence of a base,

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

In another aspect, the present invention provides a process for the Asymmetric Transfer Hydrogenation (ATH) of a metallocene-based compound of formula (V) to a metallocene-based compound of formula (IV),

Figure BDA0002357433170000051

wherein:

the asymmetric transfer hydrogenation is carried out in an aqueous solvent at a temperature greater than 60 ℃ in the presence of an asymmetric transfer hydrogenation catalyst and active formic acid; wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5;

when j is 1, n is an integer of 0 to 4; and

denotes an optically active carbon atom.

Definition of

The point of attachment of a moiety or substituent is indicated by "-". For example, -OH is attached via an oxygen atom.

"active formic acid" refers to a mixture of formic acid, tertiary amine base, and optionally water, which forms a liquid reducing agent for the ATH reaction.

"alkyl" refers to a straight or branched saturated hydrocarbon group. In certain embodiments, the alkyl group may have from 1 to 20 carbon atoms, in certain embodiments from 1 to 15 carbon atoms, in certain embodiments from 1 to 8 carbon atoms. The alkyl group may be unsubstituted. Alternatively, the alkyl group may be substituted. Unless otherwise specified, the alkyl group may be attached at any suitable carbon atom and, if substituted, may be substituted at any suitable atom. Typical alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.

The term "cycloalkyl" is used to denote a saturated carbocyclic hydrocarbon group. In certain embodiments, the cycloalkyl group may have 3 to 15 carbon atoms, in certain embodiments 3 to 10 carbon atoms, in certain embodiments 3 to 8 carbon atoms. The cycloalkyl group may be unsubstituted. Alternatively, the cycloalkyl group may be substituted. Unless otherwise specified, the cycloalkyl group may be attached at any suitable carbon atom and, if substituted, may be substituted at any suitable atom. Typical cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

"alkoxy" refers to an optionally substituted group of the formula alkyl-O-or cycloalkyl-O-, wherein alkyl and cycloalkyl are as defined above.

"aryl" refers to an aromatic carbocyclic group. The aryl group may have a single ring or multiple fused rings. In certain embodiments, the aryl group may have from 5 to 20 carbon atoms, in certain embodiments from 6 to 15 carbon atoms, in certain embodiments from 6 to 12 carbon atoms. The aryl group may be unsubstituted. Alternatively, the aryl group may be substituted. Unless otherwise specified, the aryl group may be attached at any suitable carbon atom and, if substituted, may be substituted at any suitable atom. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and the like.

"arylalkyl" refers to an optionally substituted group of the formula aryl-alkyl-, wherein aryl and alkyl are as defined above.

"aryloxy" refers to an optionally substituted group of the formula aryl-O-, wherein aryl is as defined above.

"halo", "hal" or "halo" refers to-F, -Cl, -Br and-I.

"heteroalkyl" refers to a straight or branched saturated hydrocarbon group in which one or more carbon atoms are independently substituted with one or more heteroatoms (e.g., nitrogen, oxygen, phosphorus, and/or sulfur atoms). In certain embodiments, the heteroalkyl group may have from 1 to 20 carbon atoms, in certain embodiments from 1 to 15 carbon atoms, in certain embodiments from 1 to 8 carbon atoms. The heteroalkyl group may be unsubstituted. Alternatively, the heteroalkyl group may be substituted. Unless otherwise specified, the heteroalkyl group may be attached at any suitable atom and, if substituted, may be substituted at any suitable atom. Examples of heteroalkyl groups include, but are not limited to, ethers, thioethers, primary amines, secondary amines, tertiary amines, and the like.

"heterocycloalkyl" refers to a saturated cyclic hydrocarbon group in which one or more carbon atoms are independently substituted with one or more heteroatoms (e.g., nitrogen, oxygen, phosphorus, and/or sulfur atoms). In certain embodiments, the heterocycloalkyl group may have from 2 to 15 carbon atoms, in certain embodiments from 2 to 10 carbon atoms, in certain embodiments from 2 to 8 carbon atoms. The heterocycloalkyl group can be unsubstituted. Alternatively, the heterocycloalkyl group may be substituted. Unless otherwise specified, the heterocycloalkyl group can be attached at any suitable atom and, if substituted, can be substituted at any suitable atom. Examples of heterocycloalkyl groups include, but are not limited to, epoxy, morpholinyl, piperidinyl, piperazinyl, thiiranyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, thiazolinyl, thiomorpholinyl, and the like.

"heteroaryl" refers to an aromatic carbocyclic group in which one or more carbon atoms are independently substituted with one or more heteroatoms (e.g., nitrogen, oxygen, phosphorus, and/or sulfur atoms). In certain embodiments, the heteroaryl group may have from 4 to 20 carbon atoms, in certain embodiments from 4 to 15 carbon atoms, in certain embodiments from 4 to 8 carbon atoms. The heteroaryl group may be unsubstituted. Alternatively, the heteroaryl group may be substituted. Unless otherwise specified, the heteroaryl group may be attached at any suitable atom and, if substituted, may be substituted at any suitable atom. Examples of heteroaryl groups include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, thienyl, oxadiazolyl, pyridyl, pyrimidinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, indolyl, quinolinyl, and the like.

"substituted" refers to a group in which one or more hydrogen atoms are each independently substituted with a substituent (e.g., 1, 2, 3, 4, 5, or more), which may be the same or different. This group may be substituted with one or more substituents up to the limits imposed by the stability and valence rules. The substituents are selected so that they are not adversely affected under the conditions of the ATH, acylation, amination or salt formation reaction. Examples of substituents include, but are not limited to, -halo, -CF3、-Ra、-O-Rm、-S-Rm、-NRmRn、-CN、-C(O)-Rm、-COORm、-C(S)-Rm、-C(S)ORm、-S(O)2OH、-S(O)2-Rm、-S(O)2NRmRnand-CONRmRnPreferably-halo, -CF3、-Rm、-O-Rm、-NRmRn、-COORm、-S(O)2OH、-S(O)2-Rm、-S(O)2NRmRnand-CONRmRn。RmAnd RnIndependently selected from H, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or RmAnd RnTogether with the atom to which they are attached form a heterocycloalkyl group, and wherein RmAnd RnMay be unsubstituted or further substituted as defined herein.

"metallocene group" refers to a transition metal complex group in which a transition metal atom or ion is "sandwiched" between two rings of atoms. The metallocene group may be substituted or unsubstituted. Unless otherwise specified, the metallocene group may be attached at any suitable atom and, if substituted, may be substituted at any suitable atom. Examples of transition metal atoms or ions include, but are not limited to, ruthenium, osmium, nickel, and iron. An example of a suitable ring of atoms is a cyclopentadienyl ring. One example of a metallocene group includes, but is not limited to, ferrocenyl, which comprises an fe (ii) ion sandwiched between two cyclopentadienyl rings, wherein each cyclopentadienyl ring may independently be unsubstituted or substituted.

"optically active" means a vibrating plane capable of rotating polarized light to the right or left.

"halogen anion" means F-、Cl-、Br-And I-

"oxoanion" means an anion containing one or more oxygen atoms bonded to another element.

A "monoanion" is an ion having a single negative charge. A "dianion" is an anion with two negative charges.

An "acyl" group is a moiety derived from the removal of one or more hydroxyl groups from a carboxylic acid.

A "suspension" is a heterogeneous mixture containing solid particles large enough to settle at rest.

"aqueous solvent" refers to water or a mixture of water and a water-miscible solvent.

Detailed Description

Metallocene-based compounds of the formulae (I) and (II)

In one aspect, the present invention provides a metallocene-based compound of formula (I),

Figure BDA0002357433170000081

wherein:

Ra、Rb、Rcand RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

RaMay be selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. In one embodiment, RaSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. RaA branched or straight chain alkyl group which may be substituted or unsubstituted, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (e.g. n-pentyl or neopentyl), hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or an aryl group such as phenyl, naphthyl or anthracenyl. In one embodiment, the alkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents, each of which may be the same or different, such as a halo (F, Cl, Br, or I) group or an alkoxy group, such as methoxy, ethoxy, or propoxy. The aryl group may be optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br or I), a straight or branched alkyl group (e.g. C)1-C10) Alkoxy (e.g. C)1-C10Alkoxy), straight or branched (dialkyl) amino (e.g. C)1-C10Dialkyl) amino), heterocycloalkyl (e.g. C)3-10Heterocycloalkyl, e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Suitable substituted aryl groups include, but are not limited to, 4-dimethylaminophenyl, 4-methylphenyl, 3, 5-dimethylphenyl, 4-methoxyphenyl, 4-methoxy-3, 5-dimethylphenyl, and3, 5-bis (trifluoromethyl) phenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used. In one embodiment, RaIs methyl.

RbMay be selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. In one embodiment, RbSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. In one embodiment, RbSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. RbA branched or straight chain alkyl group which may be substituted or unsubstituted, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (e.g. n-pentyl or neopentyl), hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or an aryl group such as phenyl, naphthyl or anthracenyl. In one embodiment, the alkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br, or I), or an alkoxy group such as methoxy, ethoxy, or propoxy. The aryl group may be substituted with one or more (e.g. 1, 2, 3, 4 or 5)) The substituents being optionally substituted, each of which may be the same or different, e.g. halogen radicals (F, Cl, Br or I), straight-chain or branched alkyl radicals (e.g. C)1-C10) Alkoxy (e.g. C)1-C10Alkoxy), straight or branched (dialkyl) amino (e.g. C)1-C10Dialkyl) amino), heterocycloalkyl (e.g. C)3-10Heterocycloalkyl, e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Suitable substituted aryl groups include, but are not limited to, 4-dimethylaminophenyl, 4-methylphenyl, 3, 5-dimethylphenyl, 4-methoxyphenyl, 4-methoxy-3, 5-dimethylphenyl, and 3, 5-bis (trifluoromethyl) phenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used.

RbMay or may not be present. When absent, m is 0, i.e. containing RbThe Cp ring of (A) is not further substituted. When R isbWhen present, m may be 1, 2, 3 or 4. The or each RbMay be the same or different. In one embodiment, RbAbsent, i.e., m is 0.

RcMay be selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. In one embodiment, RcSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. In one embodiment, RcSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. RcA branched or straight chain alkyl group which may be substituted or unsubstituted, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (e.g. n-pentyl or neopentyl), hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or an aryl group such as phenyl, naphthyl or anthracenyl. In one embodiment, the alkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br, or I), or an alkoxy group such as methoxy, ethoxy, or propoxy. The aryl group may be optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br or I), a straight or branched alkyl group (e.g. C)1-C10) Alkoxy (e.g. C)1-C10Alkoxy), straight or branched (dialkyl) amino (e.g. C)1-C10Dialkyl) amino), heterocycloalkyl (e.g. C)3-10Heterocycloalkyl, e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Suitable substituted aryl groups include, but are not limited to, 4-dimethylaminophenyl, 4-methylphenyl, 3, 5-dimethylphenyl, 4-methoxyphenyl, 4-methoxy-3, 5-dimethylphenyl, and 3, 5-bis (trifluoromethyl) phenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used.

RcMay or may not be present. When not present, n is 0, i.e. contains RcThe Cp ring(s) of (1) is not substituted. When R iscWhen present, n may be 1, 2, 3, 4, or 5 when j is 0, or n may be 1, 2, 3, or 4 when j is 1.

The or each RcMay be the same or different. In one embodiment, RcAbsent, i.e., n is 0.

RdMay be selected from unsubstituted C1-C20Alkyl, aryl, heteroaryl, and heteroaryl,Substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. In one embodiment, RdSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. RdA branched or straight chain alkyl group which may be substituted or unsubstituted, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (e.g. n-pentyl or neopentyl), hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or an aryl group such as phenyl, naphthyl or anthracenyl. In one embodiment, the alkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br, or I), or an alkoxy group such as methoxy, ethoxy, or propoxy. The aryl group may be optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br or I), a straight or branched alkyl group (e.g. C)1-C10) Alkoxy (e.g. C)1-C10Alkoxy), straight or branched (dialkyl) amino (e.g. C)1-C10Dialkyl) amino), heterocycloalkyl (e.g. C)3-10Heterocycloalkyl, e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Suitable substituted aryl groups include, but are not limited to, 4-dimethylaminophenyl, 4-methylphenyl, 3, 5-dimethylphenyl, 4-methoxyphenyl, 4-methoxy-3, 5-dimethylphenyl, and 3, 5-di-methylphenyl(trifluoromethyl) phenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used.

In one embodiment, RdIs absent, and j is 0.

In one embodiment, RdIs methyl and j is 1.

ReMay be selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20And (4) an aryl group. In one embodiment, ReSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20And (4) an aryl group. ReA branched or straight chain alkyl group which may be substituted or unsubstituted, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (e.g. n-pentyl or neopentyl), hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or an aryl group such as phenyl, naphthyl or anthracenyl. In one embodiment, the alkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br, or I), or an alkoxy group such as methoxy, ethoxy, or propoxy. The aryl group may be optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br or I), a straight or branched alkyl group (e.g. C)1-C10) Alkoxy (e.g. C)1-C10Alkoxy), straight or branched (dialkyl) amino (e.g. C)1-C10Dialkyl) amino), heterocycloalkyl (e.g. C)3-10Heterocycloalkyl, e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Suitable substituted aryl groups include, but are not limited to, 4-dimethylaminophenyl, 4-methylphenyl, 3,5-dimethylphenyl, 4-methoxyphenyl, 4-methoxy-3, 5-dimethylphenyl and 3, 5-bis (trifluoromethyl) phenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used. In one embodiment, ReIs methyl.

RfMay be selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20And (4) an aryl group. In one embodiment, RfSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20And (4) an aryl group. In one embodiment, RfSelected from unsubstituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen. RfA branched or straight chain alkyl group which may be substituted or unsubstituted, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (e.g. n-pentyl or neopentyl), hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or an aryl group such as phenyl, naphthyl or anthracenyl. In one embodiment, the alkyl group may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br, or I), or an alkoxy group such as methoxy, ethoxy, or propoxy. The aryl group may be optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, each of which may be the same or different, such as a halogen group (F, Cl, Br or I), a straight or branched alkyl group (e.g. C)1-C10) Alkoxy (e.g. C)1-C10Alkoxy), straight-chain or branched (dialkyl) amino(s) ((iii)E.g. C1-C10Dialkyl) amino), heterocycloalkyl (e.g. C)3-10Heterocycloalkyl, e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Suitable substituted aryl groups include, but are not limited to, 4-dimethylaminophenyl, 4-methylphenyl, 3, 5-dimethylphenyl, 4-methoxyphenyl, 4-methoxy-3, 5-dimethylphenyl, and 3, 5-bis (trifluoromethyl) phenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used. In one embodiment, RfIs methyl.

M may be selected from Fe, Ru, Os and Ni. In one embodiment, M is Fe and the compound of formula (I) is a ferrocenyl compound. In another embodiment, M is Ru. In another embodiment, M is Os. In another embodiment, M is Ni. Preferably, M is Fe.

In one embodiment, j is 0, n is an integer from 1 to 5, k is 1 or 2, and the metallocene-based compound of formula (I) is represented by formula (Ia):

z is a non-optically active anion and suitably may be selected from:

a) a monoatomic anion such as a halide anion, in which case k ═ 1; or

b) Oxyanions, e.g. (H)2PO4)-(k ═ 1) or (HPO)4)2-(k ═ 2); or

c) Non-optically active organic anions such as:

-when k is 1: CH (CH)3CO2 -(acetate) C6H5CO2 -(benzoate radical), CH3SO3 -(methanesulfonic acid group), CH3C6H4SO2 -(tosylate), HO2CCH=CHCO2 -(monoanionic fumarate), HO2C(CH2)4CO2 -(monoanionic adipate), HO2C-CO2 -(monoanionic oxalate radical),

-when k is 2:-O2CCH=CHCO2 -(dianionic fumarate),-O2C(CH2)4CO2 -(dianionic adipate radical),-O2C-CO2 -(dianionic oxalate).

In one embodiment, Z may be a monoanion (in this case k ═ 1) or a dianion (in this case k ═ 2).

In another embodiment, j is 1, n is an integer from 1 to 4, k is 1, and the metallocene-based compound of formula (I) is represented by formula (Ib):

z is a non-optically active anion and suitably may be selected from:

a) monoatomic anions such as halide anions; or

b) Oxyanions, e.g. (H)2PO4)-Or (HPO)4)2-(ii) a Or

c) Non-optically active organic anions such as:

-CH3CO2 -(acetate) C6H5CO2 -(benzoate radical), CH3SO3 -(methanesulfonic acid group), CH3C6H4SO2 -(tosylate), HO2CCH=CHCO2 -(monoanionic fumarate), HO2C(CH2)4CO2 -(monoanionic adipate), HO2C-CO2 -(monoanionic oxalate radical),

--O2CCH=CHCO2 -(dianionic fumarate),-O2C(CH2)4CO2 -(dianionic adipate radical),-O2C-CO2 -(dianionic oxalate).

Suitable metallocene-based compounds of formula (I) are salts of N, N-dimethyl- α -ferrocenylammonium cation (A), e.g. A (H)2PO4)、A*2(HPO4) Or mixtures thereof, a (OAc), a (benzoate), a (mesylate), a (tosylate), a (fumarate), a (adipate), a (oxalate):

Figure BDA0002357433170000161

a preferred metallocene-based compound of formula (I) is N, N-dimethyl- α -ferrocenylethylammonium dihydrogen phosphate (A (H)2PO4) Monohydrogen di-N, N-dimethyl- α -ferrocenyl ethylammonium phosphate (A)2(HPO4) Or mixtures thereof).

In another aspect, the present invention provides a process for the preparation of a metallocene-based compound of formula (I),

comprising reacting a compound of formula (II) with H H.tartatek(j+1)Z in a solvent to form a compound of formula (I),

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20In heteroaryl groupsThe heteroatoms are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

H A acid Hk(j+1)Z may be a non-optically active anion Z in a compound of formula (I)-Or Z2-The corresponding acid of (a). In one embodiment, H.about.k(j+1)Z may be H3PO4Fumaric acid, adipic acid, oxalic acid, benzoic acid, acetic acid, methanesulfonic acid and p-toluenesulfonic acid. In a preferred embodiment, H.tartatek(j+1)Z may be H3PO4

The process according to the invention can be carried out in the presence of a solvent. Preferably, the solvent comprises an alcohol, an ether (cyclic or open-chain, such as Tetrahydrofuran (THF) or methyl tert-butyl ether (MTBE)), an aromatic solvent (such as benzene or toluene), an ester (such as ethyl acetate), or a combination thereof. When the solvent comprises an alcohol, the preferred alcohol is at atmospheric pressure (i.e., 1.0135X 10)5Pa) is less than 160 deg.C, more preferably less than 120 deg.C, and even more preferably less than 100 deg.C. Preferred examples are methanol, ethanol, n-propanol, isopropanol, n-butanol or combinations thereof. More preferably, the alcohol is methanol, isopropanol, or a combination thereof. Methanol is particularly preferred.

Formula (II)) The concentration of the compound (b) may be 0.1 to 5M, preferably 0.9M to about 1.2M. In one embodiment, the concentration of the compound of formula (II) is about 1.1M. H (H)k(j+1)The concentration of Z may be from 0.5M to about 1M. In one embodiment, h is hk(j+1)The concentration of Z is about 0.9M. In another embodiment, hk(j+1)The concentration of Z is about 0.6M.

The reactants may be added in any suitable order, but in a preferred method of the invention, the h is reactedk(j+1)The diluted aqueous solution of Z is added to a solution of the compound of formula (II) in a solvent. Desirably, H is Hk(j+1)The diluted aqueous solution of Z was slowly added to the solution of the compound of formula (II) to avoid an uncontrolled exotherm.

In the present invention, a compound of formula (II) with Hk(j+1)The ratio between Z determines the composition and purity of the metallocene-based compound of formula (I). (II) a compound of formula (II) with h when j ═ 0 and k ═ 1k(j+1)The ratio between the equivalent values of Z may be from about 0.8:1 to about 1.25:1 and will form a mixture of unreacted compound of formula (II) and compound of formula (I) where k ═ 1. A compound of formula (II) with Hk(j+1)Suitable ratios between the equivalent values of Z include, but are not limited to, 0.80:1, 0.85:1, 0.90:1, 0.95:1, 1.00:1, 1.05:1, 1.10:1, 1.15:1, 1.20:1, 1.25: 1.

A compound of formula (II) with h, in the case where j ═ 0 and k are 2 or in the case where j ═ 1 and k ═ 1k(j+1)The ratio between the equivalent values of Z may be from about 1.15:1 to about 2.20:1 and will form a mixture of a compound of formula (I) (where k ═ 1) and a compound of formula (I) (where k ═ 2). A compound of formula (II) with Hk(j+1)Suitable ratios between the equivalent values of Z include, but are not limited to, 1.15:1, 1.20:1, 1.25:1, 1.30:1, 1.35:1, 1.40:1, 1.45:1, 1.50:1, 1.55:1, 1.60:1, 1.65:1, 1.70:1, 1.75:1, 1.80:1, 1.85:1, 1.90:1, 1.95:1, 2.00:1, 2.05:1, 2.10:1, 2.15:1, 2.20: 1.

When H is reactedk(j+1)When Z is added to the compound of formula (II), it is preferred that the temperature of the reaction mixture can be maintained at one or more temperatures of from about-15 ℃ to about 35 ℃. In one embodimentIn one embodiment, the reaction mixture is maintained at a temperature of about-10 ℃ to about 10 ℃. In another embodiment, the reaction mixture is maintained at a temperature of less than about 5 ℃. In a preferred embodiment, the reaction mixture is maintained at 0 ℃.

The reaction may be continued for a period of time of from about 30 minutes to about 2 hours, preferably about 1 hour. During this time, the reaction temperature may be varied one or more times from about-10 ℃ to about 60 ℃.

Optionally, Hk(j+1)Z may be added to the compound of formula (II) at a temperature below 160 ℃, more preferably below 120 ℃, even more preferably below 100 ℃. The reaction may be continued for a period of time of from about 30 minutes to about 2 hours, preferably about 1 hour. During this time, the reaction temperature may be varied one or more times from about 160 ℃ to about 15 ℃.

After completion of the reaction, the compound of formula (I) may be isolated from the reaction mixture by any suitable method.

The complex of formula (I) generally does not require purification, although conventional procedures can be used to purify the complex if necessary.

In one embodiment, the present invention further comprises the step of treating the metallocene-based complex of formula (I) with a base to form a complex of formula (II). The metallocene-based complex of formula (I) is preferably mixed with a solvent to obtain a suspension. The solvent may be any suitable solvent, such as an aromatic hydrocarbon (e.g., toluene). The base is preferably an aqueous solution of an alkaline hydroxide. The base may be added until the pH of the liquid is in the range of about 10 to about 11. After completion of the reaction, the compound of formula (II) may be isolated from the reaction mixture by any suitable method. Enantiomeric excess determinations were performed on samples of the compound of formula (II) by HPLC analysis.

In another aspect, the present invention provides a method of increasing the optical purity of a compound of formula (II),

Figure BDA0002357433170000191

which comprises the following steps:

a) mixing a metallocene-based compound of formula (I) with a solvent to obtain a suspension of solid particles in a liquid, wherein the mixing is carried out around the boiling point of the solvent;

b) separating the metallocene-based compound of formula (I) in solid form from the suspension of step a);

c) obtaining a compound of formula (II) from the metallocene-based compound of formula (I) of step b) in the presence of a base,

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5 and k is 1 or 2;

when j is 1, n is an integer of 0 to 4 and k is 1;

y is (j +1) Zk-Or Z(j+1)k-

Z is a non-optically active anion; and

denotes an optically active carbon atom.

In one embodiment, the aforementioned method of preparing the metallocene-based compound of formula (I) further comprises a method of increasing the optical purity of the compound of formula (II),

Figure BDA0002357433170000201

which comprises the following steps:

a) mixing a metallocene-based compound of formula (I) with a solvent to obtain a suspension of solid particles in a liquid, wherein the mixing is carried out around the boiling point of the solvent;

b) separating the metallocene-based compound of formula (I) in solid form from the suspension of step a);

c) obtaining the compound of formula (II) from the metallocene-based compound of formula (I) of step b) in the presence of a base.

Ra、Rb、Rc、Rd、Re、RfM, Y, Z, M, n, j and k are generally as described above.

A preferred compound of formula (I) is compound A (H)2PO4) And one preferred compound of formula (II) is compound B:

when the compound of formula (I) is compound A (H)2PO4) And the compound of formula (II) is compound B, the solvent comprises an alcohol. Preferred alcohols are at atmospheric pressure (i.e., 1.0135X 10)5Pa) is less than 160 deg.C, more preferably less than 120 deg.C, and even more preferably less than 100 deg.C. Preferred examples are methanol, ethanol, n-propanol, isopropanol, n-butanol or combinations thereof. More preferably, the alcohol is methanol, isopropanol, or a combination thereof. Particularly preferred is a mixture of isopropanol/methanol 99/1.

Compound A (H)2PO4) Is isolated from the suspension as a solid and isolated using conventional procedures such as filtration.

Treating the isolated compound A (H) with a base in a suitable solvent, such as toluene2PO4)。

The preferred base is NaOH 2M. The base may be added until the pH of the liquid is in the range of about 10 to about 11. After completion of the reaction, compound B may be separated from the reaction mixture by any suitable method, for example, separating the organic layer from the aqueous layer and separating compound B from the organic layer.

Determination of the enantiomeric excess was carried out on a sample of compound B by analysis with HPLC. The enantiomeric excess of the compound B can be more than or equal to 99% ee.

In one embodiment, by reacting a compound of formula (III) with a compound of formula HNReRfIn a solvent to form a compound of formula (II), thereby preparing a compound of formula (II),

Figure BDA0002357433170000211

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5;

when j is 1, n is an integer of 0 to 4; and

denotes an optically active carbon atom.

A compound of formula (III) HNReRfMay be from about 1:10 to about 1:4, preferably from about 1:6 to about 1:4 when j is 0. In one embodiment, the compound of formula (III) HNReRfMay be about 1:5.5 to 1: 4.5. In a preferred embodiment, the ratio is about 1:5. When j is 1, the compound of formula (III) HNReRfMay be from about 1:20 to about 1:8, preferably from about 1:12 to about 1: 8. In one embodiment, the compound of formula (III) HNReRfMay be about 1:11 to 1: 9. In a preferred embodiment, the ratio is about 1: 10.

The process according to the invention can be carried out in the presence of a solvent. Preferably, the solvent comprises an alcohol and C1-C8A mixture of alkanes. The solvent may further comprise water. Preferred alcohols are at atmospheric pressure (i.e., 1.0135X 10)5Pa) is less than 160 deg.C, more preferably less than 120 deg.C, and even more preferably less than 100 deg.C. Preferred examples are methanol, ethanol, n-propanol, isopropanol, n-butanol or combinations thereof. More preferably, the alcohol is methanol, isopropanol, or a combination thereof. Particular preference is given to isopropanol. The C is1-C8The alkane may be a linear alkane, a branched alkane, or a cycloalkane. Suitable alkanes are pentane (all isomers), hexane (all isomers), heptane (all isomers), octane (all isomers) or mixtures thereof. The most preferred alkanes are heptane and cyclohexane.

Alcohol C1-C8The alkane ratio may be from about 1:3 to about 1:8, preferably from about 1:4 to about 1:7, most preferably 1:5.

The reactants may be added in any suitable order, but in a preferred process of the invention, the compound of formula HNR is added to the reaction mixtureeRfTo a solution of the compound of formula (III) in a solvent. Desirably, the HNR is treatedeRfIs slowly added to the solution of the compound of formula (III)To avoid uncontrolled exotherms.

When HNR is addedeRfWhen added to the compound of formula (III), it is preferred that the temperature of the reaction mixture can be maintained at one or more temperatures of from about-15 ℃ to about 35 ℃. In one embodiment the reaction mixture is maintained at a temperature of from about-10 ℃ to about 10 ℃. In another embodiment, the reaction mixture is maintained at a temperature of less than about 5 ℃. In a preferred embodiment, the reaction mixture is maintained at 0 ℃.

The reaction may be continued for a period of time of from about 30 minutes to about 24 hours, preferably about 10 hours. During this period, the reaction temperature may be varied one or more times from about-10 ℃ to about 65 ℃, preferably about 50 ℃. After completion of the reaction, the compound of formula (II) may be isolated from the reaction mixture by any suitable method. The complex of formula (II) generally does not require purification, although if necessary, conventional procedures can be used to purify the complex.

In one embodiment, the compound of formula (III) is prepared by mixing a compound of formula (IV) with a compound of formula-LG in the presence of a base to form a compound of formula (III), wherein LG is a leaving group:

Figure BDA0002357433170000231

the compound of formula acyl-LG is preferably a carboxylic acid anhydride or an acid chloride. In these cases, LG can be-O-acyl (for carboxylic acid anhydrides) or-Cl (for acid chlorides). The most preferred compound of formula acyl-LG is acetic anhydride.

The base may be an organic or inorganic base. Preferably, the base is sodium acetate. The most preferred base is sodium acetate trihydrate (NaOAc.3H)2O)。

The reaction can be carried out (neat) in the absence of a solvent. In these cases, the compound of formula acyl-LG acts as a solvent. Suitable compounds of the formula acyl-LG are preferably carboxylic anhydrides.

Alternatively, the reaction may be carried out in the presence of a solvent. The solvent may be any suitable aprotic solvent. The solvent may beSelected from aromatic solvents (e.g. benzene or toluene), ethers (cyclic such as Tetrahydrofuran (THF), or open-chain such as methyl tert-butyl ether (MTBE)), esters (e.g. ethyl acetate, isopropyl acetate), C1-C8An alkane (e.g., pentane, hexane, heptane, octane, or mixtures thereof), dichloromethane, acetonitrile, acetone, or combinations thereof. In a preferred embodiment, the solvent is heptane.

The compound of formula (IV) and the compound of formula acyl-LG may be added in any suitable order. However, in a preferred process of the invention, the compound of formula (IV) and the base are placed in a reaction vessel together with a solvent (if used), and then the compound of formula acyl-LG is added.

When j is 0, the molar ratio of the compound of formula (IV) to the compound of formula acyl-LG may be from about 1:1 to about 1:5. Preferably, the molar ratio of the compound of formula (IV) to the compound of formula acyl-LG may be from about 1:1.5 to about 1:2, and when j ═ 1, the molar ratio of the compound of formula (IV) to the compound of formula acyl-LG may be from about 1:2.2 to 1: 8. Preferably, the molar ratio of the compound of formula (IV) to the compound of formula acyl-LG can be about 1:2.2 to 1: 2.6.

The base may be added in a molar ratio of the compound of formula (IV) to the base of about 1:0.1 to 1:5.

Alternatively, the base is Dimethylaminopyridine (DMAP).

In one embodiment, the compound of formula (IV) is prepared by Asymmetric Transfer Hydrogenation (ATH) of a metallocene-based compound of formula (V),

Figure BDA0002357433170000241

wherein:

the asymmetric transfer hydrogenation is carried out in an aqueous solvent at a temperature greater than 60 ℃ in the presence of an asymmetric transfer hydrogenation catalyst and active formic acid;

wherein

Ra、Rb、RcAnd RdIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20Aryl, unsubstituted C4-C20Heteroaryl, substituted C4-C20Heteroaryl, wherein the C4-C20The heteroatoms in the heteroaryl group are selected from sulfur, oxygen and nitrogen;

Reand RfIndependently selected from unsubstituted C1-C20Alkyl, substituted C1-C20Alkyl, unsubstituted C3-C15Cycloalkyl, substituted C3-C15Cycloalkyl, unsubstituted C5-C20Aryl, substituted C5-C20An aryl group;

m is selected from Fe, Ru, Os and Ni;

m is an integer of 0 to 4;

j is 0 or 1; and is

When j is 0, n is an integer of 0 to 5;

when j is 1, n is an integer of 0 to 4; and

denotes an optically active carbon atom.

Preferred compounds of formula (I) are compounds A (H)2PO4) Preferably the compound of formula (II) is compound B, preferably the compound of formula (III) is compound C, and preferably the mixture of formula (IV) is compound D:

Figure BDA0002357433170000251

in one embodiment, the compound of formula (III) is compound C, the compound of formula (IV) is compound D, and Dimethylaminopyridine (DMAP) may be used as a base in a process for preparing compound C from compound D.

In this case, compound a × (H)2PO4) Impurities such as DMAP & H can be separated off by further purification3PO and DMAP HOAc, comprising the steps of:

a) adding methanolTo a solution containing DMAP. H3PO4And DMAP HOAc Compound A (H)2PO4) To produce a solid-liquid mixture;

b) will contain compound A (H)2PO4) And DMAP HOAc from the solid-liquid mixture of step a);

c) adding DMAP HOAc-containing compound A (H)2PO4) Separating from the liquid of step b);

d) adding dichloromethane or acetonitrile to the separated compound a (H) containing DMAP HOAc of step c)2PO4) To produce a second solid-liquid mixture;

e) separating the solid from the second solid-liquid mixture of step d) to yield compound a (H) having a higher purity than before steps a) -e)2PO4)。

In one embodiment, the compound of formula (III) is obtained in situ, so in situ with the compound of formula HNReRfWithout further isolation prior to reaction.

Metallocene-based compounds of the formulae (IV) and (V)

The metallocene-based carbonyl compound of formula (V) is asymmetrically reduced to a metallocene-based alcohol of formula (IV):

Ra、Rb、Rc、Rdm, M, n and j are generally as described above.

Asymmetric transfer hydrogenation catalyst

The asymmetric transfer hydrogenation catalyst may be a complex of formula (VI). The complex of formula (VI) may be referred to herein as a tethered complex.

Wherein the content of the first and second substances,

R1、R2、R3、R4and R5Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, CN, -NR20R21、-COOH、COOR20、-CONH2、-CONR20R21and-CF3Wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR30R31、-COOR30、-CONR30R31and-CF3(ii) a And/or

R1And R2、R2And R3、R3And R4Or R4And R5Together form an aromatic ring comprising 6 to 10 carbon atoms, optionally substituted with one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3

R6、R7、R8And R9Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl and optionally substituted C6-20Aryloxy, wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3Or is or

R6And R7Together with the carbon atom to which they are bonded and/or R8And R9Together with the carbon atom to which they are bonded form optionally substituted C3-20Cycloalkyl or optionally substituted C2-20Cycloalkoxy, wherein the substituents are selected from one or more of: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3Or is or

R6And R7One of and R8And R9Together form an optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are independently selected from one or more of: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR20R21、-COOR20、-CONR20R21and-CF3

Provided that R is6And R7And/or R8And R9In contrast to this, the present invention is,

Figure BDA0002357433170000271

represents an optically active carbon atom;

R10is an optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted C6-10Aryl or-NR11R12Wherein the substituents are selected from one or more of the following: straight chain,Branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -Hal, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3

R11And R12Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl and optionally substituted C6-10Aryl, wherein the substituent is selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3Or is or

R11And R12Together with the nitrogen atom to which they are bonded form optionally substituted C2-10Cycloalkyl-amino, wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3

R20And R21Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN, -NR30R31、-COOR30、-CONR30R31and-CF3Wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

R30And R31Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN and-CF3Wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

A is optionally substituted straight or branched chain C2-5Alkyl, wherein the substituent is selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl and C6-10Aryloxy group, or

A is a group of formula (VII):

Figure BDA0002357433170000281

wherein p is an integer selected from 1, 2, 3 or 4;

each R40Independently selected from linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN or-CF3

q and r are independently selected from integers of 0, 1, 2 or 3, wherein q + r is 1, 2 or 3;

each R41Independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclicC3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3(ii) a Or

A is a group of formula (VIII):

Figure BDA0002357433170000282

x is O or S;

s and t are independently integers selected from 0, 1, 2 or 3, wherein s + t is 1, 2 or 3;

each R42Independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

And

hal is halogen.

When R is6And R7And/or R8And R9When not identical radicals, R6And R7And/or R8And R9The carbon atom bonded to is asymmetric. In one embodiment, R6And R7Are not the same group. In another embodiment, R8And R9Are not the same group. The asymmetric carbon atom is represented by a symbol

Figure BDA0002357433170000291

And (4) showing. The complex of formula (VI) is chiral (optically active) and the transfer hydrogenation process of the invention is an asymmetric transfer hydrogenation process.

R1、R2、R3、R4And R5Each independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, CN, -NR20R21、-COOH、COOR20、-CONH2、-CONR20R21and-CF3. In another embodiment, R1、R2、R3、R4And R5Each independently selected from hydrogen, straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH. Preferably, R1、R2、R3、R4And R5Each independently selected from hydrogen, linear C1-10Alkyl and branched C1-10An alkyl group. R1、R2、R3、R4And R5Each may be independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. For example, R1、R2、R3、R4And R5Each may be hydrogen. In another embodiment, R3May be methyl, and R1、R2、R4And R5Each may be hydrogen.

In yet another embodiment, R6、R7、R8And R9Each independently selected from hydrogen, optionally substituted straight or branched chain C1-10Alkyl, optionally substituted straight or branched C1-10Alkoxy, optionally substituted C6-10Aryl and optionally substituted C6-10Aryloxy group wherein the substituents are selected from straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH. Radical R6、R7、R8And R9Each of which may be independently selected from hydrogen and optionally substituted C6-10And (4) an aryl group. For example, R6、R7、R8And R9Each may be independently selected from hydrogen or phenyl. In one embodiment, R6And R7One of which is phenyl, and R6And R7The other is hydrogen. In one embodiment, R8And R9One of which is phenyl, and R8And R9The other is hydrogen.

In another embodimentIn the embodiment, R6And R7Together with the carbon atom to which they are bonded and/or R8And R9Together with the carbon atom to which they are bonded form optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are selected from straight or branched C1-10Straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH.

In yet another embodiment, R6And R7One of and R8And R9Together form an optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are selected from straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH.

In yet another embodiment, R10Is optionally substituted straight, branched or cyclic C1-10Alkyl, optionally substituted C6-10Aryl, wherein the substituent is selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -Hal, -OH, -CN, -NR20R21,-COOR20,-CONR20R21and-CF3. In another embodiment, the substituent is selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy radicals, -Hal or-CF3. In another embodiment, R10Is straight-chain or branched C1-10Alkyl or C6-10Aryl, optionally with one or more straight or branched C1-10Alkyl substitution. R10Examples of (b) include, but are not limited to, p-tolyl, methyl, p-methoxyphenyl, p-chlorophenyl, trifluoromethyl, 3, 5-dimethylphenyl, 2,4, 6-trimethylphenyl, 2,4, 6-triisopropylphenyl, 4-tert-butylphenyl, pentamethylphenyl, and 2-naphthyl. R10Can beMethyl or tolyl.

In another embodiment, R10is-NR11R12Wherein R is11And R12Independently selected from linear or branched C1-10Alkyl and C6-10Aryl, optionally with one or more straight or branched C1-10Alkyl substitution. -NR11R12May be- Ν Μ e2

In yet another embodiment, R11And R12Together with the nitrogen atom to which they are bonded form optionally substituted C5-10Cycloalkyl-amino, wherein the substituents are selected from straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH.

In one embodiment, A is optionally substituted straight or branched chain C2-5Alkyl, preferably optionally substituted straight or branched C3-5Alkyl, wherein the substituent is selected from the group consisting of straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl and C6-10An aryloxy group. A may be selected from- (CH)2)2-、-(CH2)3-、-(CH2)4-or- (CH)2)5-, e.g. - (CH)2)3-or- (CH)2)4-。

Alternatively, A may be a group of formula (VII), i.e. - [ C (R)41)2]q-and- [ C (R)41)2]r-the groups are ortho to each other.

Figure BDA0002357433170000311

Wherein p is an integer selected from 1, 2, 3 or 4;

each R40Independently selected from linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20An aryloxy group,-OH, -CN or-CF3

q and r are independently selected from integers of 0, 1, 2 or 3, wherein q + r is 1, 2 or 3; and

each R41Independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN or-CF3

In one embodiment, p is 0. The phenyl ring is therefore void of any R40And (4) substituting the group.

In another embodiment, each R is41Independently selected from hydrogen, linear C1-10Alkyl and branched C1-10An alkyl group. More preferably, each R41Each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. In one embodiment, each R is41Is hydrogen.

In one embodiment, q + r is 1. In another embodiment, q + r is 2. In yet another embodiment, q + r is 3.

Examples of a include, but are not limited to, the following:

Figure BDA0002357433170000312

in another embodiment, A is a group of formula (VIII):

Figure BDA0002357433170000321

wherein X is O or S;

s and t are independently selected from integers of 0, 1, 2 or 3, where s + t is 1, 2 or 3.

Each R42Independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

In one embodiment, s + t may be 1. In another embodiment, s + t may be 2. In yet another embodiment, s + t may be 3.

In one embodiment, X is O, i.e. an oxygen atom. In another embodiment, X is S, i.e. a sulfur atom.

In another embodiment, each R is42Independently selected from hydrogen, linear C1-10Alkyl and branched C1-10An alkyl group. More preferably, each R42Each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. In one embodiment, each R is42Is hydrogen.

Examples of a include, but are not limited to, the following:

Figure BDA0002357433170000322

in one embodiment, a includes, but is not limited to:

in one embodiment Hal is chlorine, bromine or iodine, preferably chlorine.

The metal complex of formula (VI) may be selected from:

Figure BDA0002357433170000331

the metal complex of formula (VI) may be selected from:

the preparation of the metal complexes of the formula (VI) is given in WO2010/106364, WO2016/042298 and EP 2609103.

The asymmetric transfer hydrogenation catalyst may be a complex of formula (IX):

Figure BDA0002357433170000341

wherein the content of the first and second substances,

R101、R102、R103、R104、R105and R106Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, CN, -NR200R201、-COOH、COOR200、-CONH2、-CONR200R201and-CF3Wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR300R301、-COOR300、-CONR300R301and-CF3(ii) a And/or

R101And R102、R102And R103、R103And R104、R104And R105Or R105And R106Together form an aromatic ring comprising 6 to 10 carbon atoms, optionally substituted with one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3

R107、R108、R109And R110Each independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substitutedLinear C of generations1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl and optionally substituted C6-20Aryloxy, wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3Or is or

R107And R108Together with the carbon atom to which they are bonded and/or R109And R110Together with the carbon atom to which they are bonded form optionally substituted C3-20Cycloalkyl or optionally substituted C2-20Cycloalkoxy, wherein the substituents are selected from one or more of: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200、-CONR200R201and-CF3Or R is107And R108One of and R109And R110Together form an optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are independently selected from one or more of: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOR200,-CONR200R201and-CF3

Provided that R is107And R108And/or R109And R110In contrast to this, the present invention is,

Figure BDA0002357433170000351

represents an optically active carbon atom;

R111is optionally substituted straight, branched or cyclic C1-10Alkyl, optionally substituted C6-10Aryl or-NR112R113Wherein the substituents are selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -Hal, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3

R112And R113Independently selected from hydrogen, optionally substituted straight, branched or cyclic C1-10Alkyl and optionally substituted C6-10Aryl, wherein the substituent is selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3(ii) a Or

R112And R113Together with the nitrogen atom to which they are bonded form optionally substituted C2-10Cycloalkyl-amino, wherein the substituents are selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3

R200And R201Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN, -NR300R301、-COOR300、-CONR300R301and-CF3Wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

R300And R301Independently selected from hydrogen, optionally substituted straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, optionally substituted straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy, optionally substituted C6-20Aryl, optionally substituted C6-20Aryloxy, -OH, -CN and-CF3Wherein the substituents are selected from one or more of the following: straight chain C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN and-CF3

And

hal' is halogen.

When R is107And R108And/or R109And R110When not identical radicals, R107And R108And/or R109And R110The carbon atom bonded to is asymmetric. In one embodiment, R107And R108Are not the same group. In another embodiment, R108And R109Are not the same group. Symbol for asymmetric carbon atom

Figure BDA0002357433170000361

And (4) showing. The complex of formula (IX) is chiral (optically active) and the transfer hydrogenation process of the invention is an asymmetric transfer hydrogenation process.

In one embodiment, R101、R102、R103、R104、R105And R106Each independently selected from hydrogen, linear C1-20Alkyl, branched or cyclic C3-20Alkyl, straight chain C1-20Alkoxy, branched or cyclic C3-20Alkoxy radical, C6-20Aryl radical, C6-20Aryloxy, -OH, -CN, -NR200R201、-COOH、COOR200、-CONH2、-CONR200R201and-CF3. In another embodiment, R101、R102、R103、R104、R105And R106Each independently selected from hydrogen, straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH. For example, R101、R102、R103、R104、R105And R106Each independently selected from hydrogen, linear C1-10Alkyl and branched C1-10An alkyl group. R101、R102、R103、R104、R105And R106May each be independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. For example, R101、R102、R103、R104、R105And R106Each may be hydrogen, i.e., the aromatic ring coordinated to the Ru atom is benzene. In another embodiment, R102May be methyl, R105May be isopropyl, and R101、R103、R104And R106Each may be hydrogen, i.e. the aromatic ring coordinated to the Ru atom is p-cymene. In another embodiment, R101、R103And R105Each is methyl, and R102、R104And R106Each is hydrogen, i.e. the aromatic ring coordinated to the Ru atom is trimethylbenzene.

In yet another embodiment, R107、R108、R109And R110Each independently selected from hydrogen, optionally substituted straight or branched chain C1-10Alkyl, optionally substituted straight or branched C1-10Alkoxy radicalRadical, optionally substituted C6-10Aryl and optionally substituted C6-10Aryloxy group wherein the substituents are selected from straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH. Radical R107,R108,R109And R110May each be independently selected from hydrogen and optionally substituted C6-10And (4) an aryl group. For example R107,R108,R109And R110May each be independently selected from hydrogen or phenyl. In one embodiment, R107And R108One of which is phenyl, and R107And R108The other is hydrogen. In one embodiment, R109And R110One of which is phenyl, and R109And R110The other is hydrogen.

In another embodiment, R107And R108Together with the carbon atom to which they are bonded and/or R109And R110Together with the carbon atom to which they are bonded form optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are selected from straight or branched C1-10Straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH.

In yet another embodiment, R107And R108One of and R109And R110Together form an optionally substituted C5-10Cycloalkyl or optionally substituted C5-10Cycloalkoxy, wherein the substituents are selected from straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH.

In yet another embodiment, R111Is optionally substituted straight, branched or cyclic C1-10Alkyl, optionally substituted C6-10Aryl, wherein the substituent is selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy, -Hal, -OH, -CN, -NR200R201,-COOR200,-CONR200R201and-CF3. In another embodiment, the substituent is selected from one or more of the following: straight, branched or cyclic C1-10Alkyl, straight-chain, branched or cyclic C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy radicals, -Hal or-CF3. In another embodiment, R111Is straight-chain or branched C1-10Alkyl or C6-10Aryl, optionally with one or more straight or branched C1-10Alkyl substitution. R111Examples of (b) include, but are not limited to, p-tolyl, methyl, p-methoxyphenyl, p-chlorophenyl, trifluoromethyl, 3, 5-dimethylphenyl, 2,4, 6-trimethylphenyl, 2,4, 6-triisopropylphenyl, 4-tert-butylphenyl, pentamethylphenyl, and 2-naphthyl. R111And may be methyl or tolyl.

In another embodiment, R111is-NR112R113Wherein R is112And R113Independently selected from linear or branched C1-10Alkyl and C6-10Aryl, optionally with one or more straight or branched C1-10Alkyl substitution. -NR112R113May be- Ν Μ e2

In yet another embodiment, R112And R113Together with the nitrogen atom to which they are bonded form optionally substituted C5-10Cycloalkyl-amino, wherein the substituents are selected from straight or branched C1-10Alkyl, straight or branched C1-10Alkoxy radical, C6-10Aryl radical, C6-10Aryloxy and-OH.

Hal' may be chlorine, bromine or iodine, for example chlorine.

The metal complex of formula (IX) may be selected from:

Figure BDA0002357433170000381

the preparation of the metal complex of formula (IX) is given in EPO916637B (belonging to Takasago International corporation and others).

Asymmetric transfer hydrogenation

Transfer hydrogenation is the addition of hydrogen from a non-hydrogen source to the molecule. Asymmetric hydrogen transfer reactions reduce prochiral molecules (e.g., metallocene-based compounds of formula (V)) to optically active products (e.g., metallocene-based compounds of formula (IV)).

In the present invention, the ATH reaction is carried out in an aqueous solvent in the presence of an ATH catalyst and active formic acid.

The ATH catalyst and the active formic acid are combined in an aqueous solvent. In one embodiment, the aqueous solvent is water. Water may be introduced into the ATH reaction as such or as part of the active formic acid mixture. In another embodiment, the aqueous solvent is water and at least one water miscible solvent. Any suitable water miscible solvent that is capable of dissolving the ATH catalyst and the active formic acid and does not adversely affect the chemical conversion of compound (V) to compound (IV) and/or the enantiomeric purity of compound (IV)) may be used. When the ATH catalyst is a complex of formula (VI), the aqueous solvent may be selected from the group consisting of water, amide solvents, cyclic ether solvents, and ester solvents. Examples of amide solvents include, but are not limited to, Dimethylformamide (DMF) and Dimethylacetamide (DMA). Examples of cyclic ether solvents include, but are not limited to, Tetrahydrofuran (THF) and 1, 4-dioxane. Mixtures of water and water miscible solvents include, but are not limited to, water and THF, water and 1, 4-dioxane, water and DMF, or water and DMA. Some ester solvents are water soluble in small amounts. These ester solvents include, but are not limited to, ethyl acetate and propyl acetate (iso or normal).

The ATH reaction can be monophasic (i.e., homogeneous) or biphasic. The ATH reaction can be biphasic if the aqueous phase contains measurable amounts of dissolved organic solvent.

The ATH reaction can be carried out at a temperature greater than 60 c and less than the boiling point of the reaction mixture. The boiling point of the reaction mixture may vary depending on the aqueous solvent used. In one embodiment, the ATH reaction is carried out at one or more temperatures from > about 60 ℃ to ≦ about 100 ℃. In some embodiments, the hydrogenation is carried out at one or more temperatures of ≧ about 65 ℃. In some embodiments, the hydrogenation is carried out at one or more temperatures ≧ about 70 ℃. In some embodiments, the hydrogenation is carried out at one or more temperatures of ≧ about 75 ℃. In some embodiments, the hydrogenation is carried out at one or more temperatures of ≦ about 95 ℃. In some embodiments, the hydrogenation is carried out at one or more temperatures of ≦ about 90 deg.C. In some embodiments, the hydrogenation is carried out at one or more temperatures of ≦ about 85 deg.C. In a preferred embodiment, the hydrogenation is carried out at one or more temperatures from ≥ about 77 ℃ to about ≤ 85 ℃, e.g., about 80 ℃.

The hydrogen donor in the ATH reaction is the reactive formic acid. "active formic acid" refers to a mixture of formic acid, tertiary amine base, and optionally water, which forms a liquid reducing agent for the ATH reaction. When water is added to the ATH reaction as a single component of the reaction, the active formic acid can be a mixture of formic acid and a tertiary organic base.

Alternatively or additionally, the active formic acid may be a mixture of formic acid, a tertiary amine base, and water. In this case, it may not be necessary to add additional water to the reaction mixture as a single component. Tertiary amine bases include, but are not limited to, NR 'R "R'", where R ', R "and R'" are independently substituted or unsubstituted C1-20An alkyl group. Tertiary amines include, but are not limited to, trimethylamine and triethylamine, e.g., triethylamine. In one embodiment, the active formic acid is a mixture of concentrated formic acid, triethylamine, and water. The active formic acid may be deoxygenated prior to use, for example, by bubbling an inert gas such as argon or nitrogen through the liquid.

The molar ratio of formic acid to tertiary amine may be from about 1:1 to about 1.5:1mol, i.e., formic acid may be in slight excess. In one embodiment, the molar ratio of formic acid to tertiary amine is about 1:1 mol. In another embodiment, the molar ratio of formic acid to tertiary amine is about 1.1:1 mol. In yet another embodiment, the molar ratio of formic acid to tertiary amine is about 1.2:1 mol. In yet another embodiment, the molar ratio of formic acid to tertiary amine is about 1.4:1 mol.

When the formic acid tertiary amine liquid is diluted with water, the concentration of formic acid tertiary amine may be 1M:1M to about 1.2M: 1M. In one embodiment, the molar ratio is about 1M: 1M. In another embodiment, the molar ratio is about 1.1M: 1M. In yet another embodiment, the molar ratio is about 1.2M: 1M.

When the molar ratio of formic acid to tertiary amine in water is from about 1M:1M to about 1.2M:1M, then the pH of the liquid is from about 4 to about 10. It has been found that slight changes in the concentration of formic acid, tertiary amine, results in significant changes in pH. In one embodiment, the pH of 1M:1M formic acid triethylamine in water is about pH 6.5.

In certain embodiments, the active formic acid is not an azeotropic mixture of formic acid and triethylamine, i.e., the ratio of formic acid to triethylamine is 5M: 2M.

Molar ratio of active formic acid/carbonyl to be reduced (i.e., -COR)aor-CORd) May be about 1:1 to about 1.5:1mol, i.e., the active formic acid may be in slight excess. In one embodiment, the molar ratio of active formic acid/carbonyl to be reduced is about 1:1 mol. In another embodiment, the molar ratio of active formic acid/carbonyl to be reduced is about 1.1:1 mol. In yet another embodiment, the molar ratio of active formic acid/carbonyl to be reduced is about 1.2:1 mol. In yet another embodiment, the molar ratio of active formic acid/carbonyl to be reduced is about 1.4:1 mol.

The substrate/catalyst (S/C) molar ratio of the metallocene-based compound of formula (V) to the ATH catalyst can be from about 100:1 to about 2000: 1. In some embodiments, the S/C molar ratio may be ≧ about 150: 1. In some embodiments, the S/C molar ratio may be ≧ about 200: 1. In some embodiments, the S/C molar ratio may be ≧ about 250: 1. In some embodiments, the S/C molar ratio may be ≧ about 300: 1. In some embodiments, the S/C molar ratio may be ≧ about 350: 1. In some embodiments, the S/C molar ratio may be ≧ about 400: 1. In some embodiments, the S/C molar ratio may be ≧ about 450: 1. In some embodiments, the S/C molar ratio may be ≧ about 500: 1. In some embodiments, the S/C molar ratio may be ≧ about 550: 1. In some embodiments, the S/C molar ratio may be ≧ about 600: 1. In some embodiments, the S/C molar ratio may be ≦ about 2000: 1. In some embodiments, the S/C molar ratio may be ≦ about 1750: 1. In some embodiments, the S/C molar ratio may be ≦ about 1500: 1. In some embodiments, the S/C molar ratio may be less than or equal to about 1250: 1. In some embodiments, the S/C molar ratio may be ≦ about 1000: 1. In some embodiments, the S/C molar ratio may be ≦ about 750: 1. In some embodiments, the S/C molar ratio may be ≦ about 700: 1. In one embodiment, the S/C molar ratio may be ≧ 600:1 to ≦ about 700:1, such as about 620:1, or 645: 1. It is believed that the synthesis of compound (IV), e.g. chiral ferrocenyl ethanol, at S/C molar ratios >100:1 or higher, especially at high S/C molar ratios > 600:1, has not been described before. The ability to carry out the ATH reaction at high S/C molar ratios allows the development of commercially viable industrial processes for the preparation of compound (IV).

The ATH reaction can be carried out under an inert atmosphere such as nitrogen or argon. In this case, it is desirable that the reaction is carried out in an open system, for example using a bubbler, to release the CO2By-products. The inert gas purges CO from the reaction2

The ATH reaction was carried out for a period of time until completion of the reaction was confirmed. Completion of the reaction can be determined by in-process analysis, for example by sampling the reaction mixture and analyzing it by HPLC to determine conversion and enantiomeric excess. In certain embodiments, the conversion of compound (V) to compound (IV) is > about 50%. In certain embodiments, the conversion is ≧ about 60%. In certain embodiments, the conversion is ≧ about 70%. In certain embodiments, the conversion is ≧ about 80%. In certain embodiments, the conversion is ≧ about 85%. In certain embodiments, the conversion is ≧ about 90%. In certain embodiments, the conversion is ≧ about 95%. In certain embodiments, the conversion is ≧ about 97%. In certain embodiments, the conversion is substantially 100%. Typically, the reaction is complete in about 48 hours. The enantiomeric excess of the compound (B) may be not less than 90% ee, not less than 91% ee, not less than 92% ee, not less than 93% ee, not less than 94% ee, not less than 95% ee, not less than 96% ee, not less than 97% ee, not less than 98% ee, not less than 99% ee or higher.

The reagents may be added in any suitable order. In this connection, the reactor can be charged with compound (V) and subsequently with active formic acid and ATH catalyst. The active formic acid can be added at one time.Alternatively, the active formic acid may be added slowly and continuously over a period of time (e.g., using a syringe pump) and/or in portions during the course of the reaction. Since the ATH reaction produces 1mol of CO per 1mol of reduced carbonyl2/, a large amount of gas is thus released. Also, slow/continuous and/or portion-wise addition of the active formic acid helps to control the accumulation of gases by limiting the amount of reducing agent present in the reaction vessel. The ATH catalyst can be added to the reaction mixture in solid form or as a solution in one of the water-miscible solvents described above (e.g., THF). The reaction mixture may be stirred at a suitable temperature for a suitable time.

After completion of the reaction, the reaction vessel may be cooled to ambient temperature and optionally purged with one or more inert gas/vacuum cycles (e.g., 1, 2, 3, 4, or 5 cycles) to remove excess carbon dioxide. The reaction mixture may be treated with an ester solvent (e.g., ethyl acetate), washed one or more times (e.g., 1, 2, 3, or more times) with water or brine, dried (e.g., over magnesium sulfate), and filtered (e.g., through a pad of silica and magnesium sulfate). The product compound (IV) may be obtained by removing the organic solvent, for example by increasing the temperature or decreasing the pressure using distillation or stripping methods well known in the art.

Compound (IV) may be further treated with a hot alkane solvent (e.g., pentane, hexane, or heptane), which causes compound (IV) to precipitate or crystallize. The solid compound (IV) may then be washed with additional alkane solvent and dried. Drying may be carried out using known methods, for example at a temperature of about 10-60 deg.C, for example 20-40 deg.C, at 0.1-30 mbar for about 1 hour to about 5 days.

The separation yield of the compound (IV) may be not less than 70%, not less than 71%, not less than 72%, not less than 73%, not less than 74%, not less than 75% or more. In certain embodiments, the isolated yield of compound (B) is ≧ 76%. In certain embodiments, the isolated yield of compound (IV) is 80% or greater. In certain embodiments, the isolated yield of compound (IV) is > 83%. In certain embodiments, the isolated yield of compound (IV) is 85% or greater. In certain embodiments, the isolated yield of compound (IV) is ≧ 90%.

Compound (IV) prepared by the process of the present invention is pure. In certain embodiments, the chemical purity of compound (IV) is ≧ 90%, ≧ 91%, ≧ 92%,. 93%,. 94%,. 95% or more. In certain embodiments, the chemical purity of Compound (IV) is 95% or greater. In certain embodiments, the chemical purity of Compound (IV) is ≧ 96%. In certain embodiments, the chemical purity of Compound (IV) is 97% or greater. In certain embodiments, the chemical purity of Compound (IV) is 98% or greater. In certain embodiments, the chemical purity of Compound (IV) is 99% or greater.

The enantiomeric excess of the isolated compound (IV) can be greater than or equal to 90% ee, greater than or equal to 91% ee, greater than or equal to 92% ee, greater than or equal to 93% ee, greater than or equal to 94% ee, greater than or equal to 95% ee, greater than or equal to 96% ee, greater than or equal to 97% ee, greater than or equal to 98% ee, greater than or equal to 99% ee or higher.

The compounds of formula (V) can be obtained, for example, by the method described by Gokel et al (j. chem. ed.1972, 49, 4, 294).

Conversion of the metallocene-based alcohol of formula (IV) into a ligand useful for asymmetric catalysis

The metallocene-based alcohols of formula (IV) are key intermediates for the preparation of various chiral metallocene-based ligands by methods known in the art (see, e.g., Schaarschmidt and Lang, Organometallics, 2013, 32, 5668-5704).

For example, the metallocene-based alcohol of formula (IV) can be converted into a Bophoz ligand or a Josiphos ligand. In this case, M is Fe, and M is 0, 1, 2 or 3 (but not 4), and with-RaAt least one of the carbon atoms ortho to the C H (oh) group must be unsubstituted (i.e., -H). and-RaAt least one of the carbon atoms ortho to the C H (oh) group must be unsubstituted (i.e. -H) to allow a phosphorus-containing group to be chemically introduced into the ferrocenyl compound by methods known in the art.

When the ligand is a Josiphos ligand, the ligand may be of formula (La) or (Lb):

Figure BDA0002357433170000431

wherein the content of the first and second substances,

Rwand RxIndependently selected from unsubstituted C1-20Alkyl, substituted C1-20Alkyl, unsubstituted C3-20Cycloalkyl, substituted C3-20Cycloalkyl, unsubstituted C1-20Alkoxy, substituted C1-20Alkoxy, unsubstituted C5-20Aryl, substituted C5-20Aryl, unsubstituted C1-20Heteroalkyl, substituted C1-20Heteroalkyl, unsubstituted C2-20Heterocycloalkyl, substituted C2-20Heterocycloalkyl, unsubstituted C4-20Heteroaryl and substituted C4-20A heteroaryl group;

Ryand RzIndependently selected from unsubstituted C1-20Alkyl, substituted C1-20Alkyl, unsubstituted C3-20Cycloalkyl, substituted C3-20Cycloalkyl, unsubstituted C1-20Alkoxy, substituted C1-20Alkoxy, unsubstituted C5-20Aryl, substituted C5-20Aryl, unsubstituted C1-20Heteroalkyl, substituted C1-20Heteroalkyl, unsubstituted C2-20Heterocycloalkyl, substituted C2-20Heterocycloalkyl, unsubstituted C4-20Heteroaryl and substituted C4-20A heteroaryl group; and

Raas defined above.

In one embodiment, RaSelected from unsubstituted C1-20Alkyl and substituted C1-20An alkyl group. In one embodiment, RaIs unsubstituted branched or straight-chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl. Preferably, RaIs methyl.

In one embodiment, RwAnd RxIndependently selected from substituted or unsubstituted branched or straight chain alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cycloPentyl, cyclohexyl or adamantyl, aryl such as phenyl, naphthyl or anthracenyl, and heteroaryl such as furanyl. In one embodiment, alkyl groups may be optionally substituted with one or more substituents, such as halogen (-F, -Cl, -Br, or-I), or alkoxy groups such as methoxy, ethoxy, or propoxy. The aryl group may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino group, C3-10Heterocycloalkyl (e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Heteroaryl groups may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino or tri (halo) methyl (e.g. F)3C-). Preferably, RwAnd RxAnd is selected from the group consisting of tert-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3, 5-dimethylphenyl, 2-methylphenyl and 2-furyl, most preferably tert-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl and 2-furyl.

In one embodiment, RyAnd RzIndependently selected from substituted or unsubstituted branched or straight chain alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, aryl groups such as phenyl, naphthyl or anthracenyl, and heteroaryl groups such as furanyl. In one embodiment, the alkyl group may be optionally substituted with one or more substituents, such as halogen (-F, -Cl, -Br, or-I), or alkoxy groups such as methoxy, ethoxy, or propylAn oxy group. The aryl group may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino group, C3-10Heterocycloalkyl (e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Heteroaryl groups may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino or tri (halo) methyl (e.g. F)3C-). Preferably, RyAnd RzAnd is selected from the group consisting of tert-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3, 5-dimethylphenyl, 2-methylphenyl and 2-furyl, most preferably tert-butyl, cyclohexyl, phenyl, 3, 5-dimethylphenyl and 2-methylphenyl.

In one embodiment, the ligand of formula (La) is selected from:

(R) -1- [ (S) -2- (diphenylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(R) -1- [ (S) -2- (diphenylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(R) -1- [ (S) -2- (dicyclohexylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(R) -1- [ (S) -2- (dicyclohexylphosphino) ferrocenyl ] ethyldiphenylphosphine,

(R) -1- [ (S) -2- (diphenylphosphino) ferrocenyl ] ethyldi-3, 5-xylylphosphine,

(R) -1- [ (S) -2- (bis-3, 5-bis (trifluoromethyl) phenylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(R) -1- [ (S) -2- (di-4-methoxy-3, 5-dimethylphenylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(R) -1- [ (S) -2- (di-3, 5-bis (trifluoromethyl) phenylphosphino) ferrocenyl ] ethyl di-3, 5-dimethylphenylphosphine,

(R) -1- [ (S) -2- (dicyclohexylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(R) -1- [ (S) -2- (bis- (4-trifluoromethyl) phenylphosphino) ferrocenyl ] ethyl-di-tert-butylphosphine,

(R) -1- [ (S) -2- (di-4-methoxy-3, 5-dimethylphenylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(R) -1- [ (S) -2- (di-2-furylphosphino) ferrocenyl ] ethyldi-3, 5-xylylphosphine,

(R) -1- [ (S) -2- (di-2-furylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(R) -1- [ (S) -2- (di-1-naphthylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(R) -1- [ (S) -2- (di-1-naphthylphosphino) ferrocenyl ] ethyldi-3, 5-xylylphosphine,

(R) -1- [ (S) -2- (di-4-methoxy-3, 5-dimethylphenylphosphino) ferrocenyl ] ethyl di-3, 5-dimethylphenylphosphine,

(R) -1- [ (S) -2- (di-4-methoxy-3, 5-dimethylphenylphosphino) ferrocenyl ] ethyldi- (2-methylphenyl) phosphine,

(R) -1- [ (S) -2- (di-2-furylphosphino) ferrocenyl ] ethyldi- (2-methylphenyl) phosphine,

(R) -1- [ (S) -2- (di-tert-butylphosphino) ferrocenyl ] ethyldiphenylphosphine,

(R) -1- [ (S) -2- (di-tert-butylphosphino) ferrocenyl ] ethylbis- (2-methylphenyl) phosphine,

(R) -1- [ (S) -2- (diphenylphosphino) ferrocenyl ] ethyldiphenylphosphine,

(R) -1- [ (S) -2- (diphenylphosphino) ferrocenyl ] ethyldi (adamantyl) phosphine, and

(R) -1- [ (S) -2- (di (adamantyl) phosphino) ferrocenyl ] ethyldiphenylphosphine.

In one embodiment, the ligand of formula (Lb) is selected from:

(S) -1- [ (R) -2-bis (phenylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(S) -1- [ (R) -2-bis (phenylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(S) -1- [ (R) -2-bis (cyclohexylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(S) -1- [ (R) -2-bis (cyclohexylphosphino) ferrocenyl ] ethyldiphenylphosphine,

(S) -1- [ (R) -2-bis (phenylphosphino) ferrocenyl ] ethyldi-3, 5-dimethylphenylphosphine,

(S) -1- [ (R) -2-bis- (3, 5-bis (trifluoromethyl) phenylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(S) -1- [ (R) -2-bis- (4-methoxy-3, 5-dimethyl) phenylphosphino) ferrocenyl ] ethyldicyclohexylphosphine,

(S) -1- [ (R) -2-bis- (3, 5-bis (trifluoromethyl) phenylphosphino) ferrocenyl ] ethyl-di-3, 5-dimethylphenylphosphine,

(S) -1- [ (R) -2-bis (cyclohexylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(S) -1- [ (R) -2-bis- ((4-trifluoromethyl) phenylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(S) -1- [ (R) -2-bis- (4-methoxy-3, 5-dimethyl) phenylphosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(S) -1- [ (R) -2-bis- (2-furyl) phosphino) ferrocenyl ] ethyldi-3, 5-xylylphosphine,

(S) -1- [ (R) -2-bis- (2-furyl) phosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(S) -1- [ (R) -2-bis (1-naphthyl) phosphino) ferrocenyl ] ethyl di-tert-butylphosphine,

(S) -1- [ (R) -2-di (1-naphthyl) phosphino) ferrocenyl ] ethyldi-3, 5-xylylphosphine,

(S) -1- [ (R) -2-bis- (4-methoxy-3, 5-dimethyl) phenylphosphino) ferrocenyl ] ethyldi-3, 5-dimethylphenylphosphine,

(S) -1- [ (R) -2-bis- (4-methoxy-3, 5-dimethyl) phenylphosphino) ferrocenyl ] ethylbis- (2-methylphenyl) phosphine,

(S) -1- [ (R) -2-bis- (2-furyl) phosphino ferrocenyl ] ethylbis- (2-methylphenyl) phosphine,

(S) -1- [ (R) -2-di (tert-butylphosphino) ferrocenyl ] ethyldiphenylphosphine,

(S) -1- [ (R) -2-di (tert-butylphosphino) ferrocenyl ] ethyldi- (2-methylphenyl) phosphine,

(S) -1- [ (R) -2-diphenylphosphinoferrocenyl ] ethyldiphenylphosphine,

(S) -1- [ (R) -2- (diphenylphosphino) ferrocenyl ] ethyldi (adamantyl) phosphine, and

(S) -1- [ (R) -2- (di (adamantyl) phosphino) ferrocenyl ] ethyldiphenylphosphine.

When the ligand is a Bophoz ligand, then the ligand may be of formula (Lc) or (Ld):

Figure BDA0002357433170000471

wherein the content of the first and second substances,

Rwand RxIndependently selected from unsubstituted C1-20Alkyl, substituted C1-20Alkyl, unsubstituted C3-20Cycloalkyl, substituted C3-20Cycloalkyl, unsubstituted C1-20Alkoxy, substituted C1-20Alkoxy, unsubstituted C5-20Aryl, substituted C5-20Aryl, unsubstituted C1-20Heteroalkyl, substituted C1-20Heteroalkyl, unsubstituted C2-20Heterocycloalkyl, substituted C2-20Heterocycloalkyl, unsubstituted C4-20Heteroaryl and substituted C4-20A heteroaryl group;

Ryselected from unsubstituted C1-20Alkyl, substituted C1-20Alkyl, unsubstituted C3-20Cycloalkyl, substituted C3-20Cycloalkyl, unsubstituted C1-20Alkoxy, substituted C1-20Alkoxy, unsubstituted C5-20Aryl, substituted C5-20Aryl, unsubstituted C1-20Heteroalkyl, substituted C1-20Heteroalkyl, unsubstituted C2-20Heterocycloalkyl, substituted C2-20Heterocycloalkyl, unsubstituted C4-20Heteroaryl and substituted C4-20A heteroaryl group;

Rzand Rz'Independently selected from unsubstituted C1-20Alkyl, substituted C1-20Alkyl radicals, not takingSubstituted C3-20Cycloalkyl, substituted C3-20Cycloalkyl, unsubstituted C1-20Alkoxy, substituted C1-20Alkoxy, unsubstituted C5-20Aryl, substituted C5-20Aryl, unsubstituted C1-20Heteroalkyl, substituted C1-20Heteroalkyl, unsubstituted C2-20Heterocycloalkyl, substituted C2-20Heterocycloalkyl, unsubstituted C4-20Heteroaryl and substituted C4-20A heteroaryl group; and

Raas defined above.

In one embodiment, RaSelected from unsubstituted C1-20Alkyl and substituted C1-20An alkyl group. In one embodiment, RaIs unsubstituted branched or straight-chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl. Preferably, RaIs methyl.

In one embodiment, RwAnd RxIndependently selected from substituted or unsubstituted branched or straight chain alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, aryl groups such as phenyl, naphthyl or anthracenyl, and heteroaryl groups such as furanyl. In one embodiment, alkyl groups may be optionally substituted with one or more substituents, such as halogen (-F, -Cl, -Br, or-I), or alkoxy groups such as methoxy, ethoxy, or propoxy. The aryl group may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino group, C3-10Heterocycloalkyl (e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Heteroaryl may optionally be substituted with oneOr substituted by more (e.g. 1, 2, 3, 4 or 5) substituents, e.g. halogen (-F, -Cl, -Br or-I), straight-chain or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino or tri (halo) methyl (e.g. F)3C-). Preferably, RwAnd RxAnd is selected from the group consisting of tert-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3, 5-dimethylphenyl, 2-methylphenyl and 2-furyl, most preferably tert-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl and 2-furyl.

In one embodiment, RySelected from substituted or unsubstituted branched or straight chain alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, aryl groups such as phenyl, naphthyl or anthracenyl, and heteroaryl groups such as furanyl. In one embodiment, alkyl groups may be optionally substituted with one or more substituents, such as halogen (-F, -Cl, -Br, or-I), or alkoxy groups such as methoxy, ethoxy, or propoxy. The aryl group may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino group, C3-10Heterocycloalkyl (e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Heteroaryl groups may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino or tri (halo) methyl (e.g. F)3C-)。RyMay be selected from methyl, t-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3, 5-dimethylphenyl, 2-methylphenyl and 2-furyl, most preferably methyl, t-butyl, cyclohexyl, phenyl, 3, 5-dimethylphenyl and 2-methylphenyl.

In one embodiment, RzAnd Rz'Independently selected from substituted or unsubstituted branched or straight chain alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, aryl groups such as phenyl, naphthyl or anthracenyl, and heteroaryl groups such as furanyl. In one embodiment, alkyl groups may be optionally substituted with one or more substituents, such as halogen (-F, -Cl, -Br, or-I), or alkoxy groups such as methoxy, ethoxy, or propoxy. The aryl group may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino group, C3-10Heterocycloalkyl (e.g. morpholinyl and piperidinyl) or tri (halo) methyl (e.g. F)3C-). Heteroaryl groups may optionally be substituted with one or more (e.g. 1, 2, 3, 4 or 5) substituents, such as halogen (-F, -Cl, -Br or-I), straight or branched C1-C10Alkyl (e.g. methyl), C1-C10Alkoxy, straight or branched C1-C10(dialkyl) amino or tri (halo) methyl (e.g. F)3C-). Preferably, RzAnd Rz'And is selected from the group consisting of tert-butyl, cyclohexyl, phenyl, 3, 5-bis (trifluoromethyl) phenyl, 4-methoxy-3, 5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3, 5-dimethylphenyl, 2-methylphenyl and 2-furyl, most preferably tert-butyl, cyclohexyl, phenyl, 3, 5-dimethylphenyl and 2-methylphenyl.

In one embodiment, the ligand (Lc) may be (R) -Me-Bophoz.

In one embodiment, the ligand (Ld) may be (S) -Me-Bophoz.

The metallocene-based alcohols of formula (IV) (where j ═ 1) can be converted into optically active metallocene-based ligands, such as those described in US5760264 (belonging to Lonza, AG). In this case, M is Fe, Ru or Ni, M is 0, 1, 2 or 3 (but not 4), and n is 0, 1, 2 or 3 (but not 4), and with-RaC*H (OH) and-RdC*At least one of the carbon atoms ortho to each of the H (OH) groups must be unsubstituted (i.e., -H). and-RaC*H (OH) and-RdC*At least one of the carbon atoms ortho to the H (OH) group must be unsubstituted (i.e., -H) for the chemical introduction of the phosphorus-containing group into the metallocene-based compound.

Other preferences

Each and every compatible combination of the above-described embodiments is expressly disclosed herein as if each and every combination was individually and explicitly recited.

Various additional aspects and embodiments of the invention will be apparent to those skilled in the art in view of this disclosure.

As used herein, "and/or" means that each of the two specified features or components are specifically disclosed, with or without the other. For example, "a and/or B" means that each of (i) a, (ii) B, and (iii) a and B are specifically disclosed, as if each were individually recited herein.

Unless the context dictates otherwise, the descriptions and definitions of the above features are not limited to any particular aspect or embodiment of the invention and apply equally to all aspects and embodiments described.

Certain aspects and embodiments of the present invention will now be described by way of the following non-limiting examples.

57页详细技术资料下载
上一篇:一种医用注射器针头装配设备
下一篇:烯烃直接氧化为含氧物质

网友询问留言

已有0条留言

还没有人留言评论。精彩留言会获得点赞!

精彩留言,会给你点赞!

技术分类